Status:
COMPLETED
Montelukast - a Treatment Choice for COVID-19
Lead Sponsor:
University of Sargodha
Collaborating Sponsors:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shaukat Khanum Memorial Cancer Hospital & Research Centre
Conditions:
Covid19
SARS-CoV-2 Infection
Eligibility:
All Genders
20-80 years
Brief Summary
The current study aimed to make a therapeutic comparison and effectiveness of Hydroxychloroquine (HCQ) and Montelukast (ML) in COVID-19 patients in addition to the standard of care. The safety and eff...
Detailed Description
To date, no specific medication is available for COVID-19. Many FDA-approved drugs, including antivirals, antibacterials, and anti-inflammatory compositions are being tested with the intention of repu...
Eligibility Criteria
Inclusion
- Patients with diagnosed COVID-19
- Patients who are not directly admitted to ICU
Exclusion
- Patients, who were already on immunosuppressants
- Patients with age \> 80
- Patient with any known allergies to montelukast
Key Trial Info
Start Date :
February 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 20 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04714515
Start Date
February 20 2020
End Date
April 20 2020
Last Update
January 19 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
Shanghai, China
2
Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan
Lahore, Punjab Province, Pakistan, 54600